Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

20091,483 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet

Volume 374, Issue 9683, pp. 39-47

Field-Weighted Citation Impact: 101.37